Unichem Labs USFDA Inspection at Kolhapur API Unit

    Synopsis:


    Unichem Laboratories Limited reported that a USFDA inspection at its Kolhapur API facility from 27 January to 2 February 2026 ended with five procedural observations, none linked to data integrity, as per NSE and BSE filings.


    Source:
    Unichem Laboratories Limited Press Release (NSE Exchange Filings) | Published on Feb 02, 2026

    Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

    As quoted in the press release from Unichem Laboratories Limited (NSE Exchange Filings), the United States Food and Drug Administration inspected the company’s Kolhapur API facility. The inspection was carried out between 27 January 2026 and 2 February 2026.

    The company informed the stock exchanges that the inspection ended with five observations. These observations were procedural in nature. The company also stated that none of the observations were linked to data integrity.

    The disclosure was submitted to the National Stock Exchange of India and BSE Limited on 2 February 2026. The filing was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

    Unichem Laboratories Limited stated that it will submit its responses to the USFDA within the stipulated 15-day period. The update was shared during market hours as part of regulatory disclosure requirements.

    Unichem Laboratories Limited and share price activity reflected trading following the exchange filing.

    Also Read: Brigade Hotel Ventures Commits ₹1100 Crore to Chennai Projects

     

    Unichem Laboratories Ltd

    Trade

    539.952.60 (0.48 %)

    Updated - 27 July 2026
    552.30day high
    DAY HIGH
    538.00day low
    DAY LOW
    51339
    VOLUME (BSE)

    Key Takeaways

    • USFDA inspected the Kolhapur API facility

    • The inspection took place from 27 January to 2 February 2026

    • Five observations were issued after the inspection

    • The observations were procedural

    • No data integrity issues were reported

    • The company will respond within 15 days

    USFDA Inspection at Kolhapur API Facility

    The inspection was conducted at the Kolhapur unit. The facility is used for manufacturing active pharmaceutical ingredients.

    The inspection lasted for six days. At the end of the process, the USFDA issued five observations.

    The company clarified that these observations were procedural in nature. It also stated that none of the observations were related to data integrity.

    The company confirmed that it will submit its responses within the required time frame. This information was shared through an exchange filing.

    Regulatory Disclosure Details

    The disclosure was addressed to both NSE and BSE. It was signed by the Head – Legal and Company Secretary of Unichem Laboratories Limited.

    The filing was made for information and record purposes. No financial estimates or forward-looking statements were included.

    The disclosure focused only on the inspection outcome and the response timeline.

    Inspection Summary

    Particulars

    Details

    Facility

    Kolhapur API Facility

    Inspecting Authority

    United States Food and Drug Administration

    Inspection Period

    27 January to 2 February 2026

    Observations Issued

    Five

    Nature Of Observations

    Procedural

    Data Integrity Issues

    None

    Response Timeline

    Within 15 days

    Unichem Laboratories Share Price Update

    Unichem Laboratories Limited's share price data on the National Stock Exchange showed the stock trading at ₹377.95 as of 15:30 PM IST on 2 February 2026.

    The share price rose by ₹2.55, or 0.68 per cent, from the previous close. The stock opened at ₹373.30 during the session.

    The stock touched a high of ₹379.80 and a low of ₹365.05. The previous closing price was ₹375.40. Unichem Laboratories Limited's share price movement were tracked after the disclosure.

    About Unichem Laboratories Limited

    Unichem Laboratories Limited operates in the pharmaceutical sector. The company manufactures formulations and active pharmaceutical ingredients.

    It has manufacturing facilities in India. The company supplies products to domestic and international markets, as stated in its regulatory filings.

    Also Read: IRB Infrastructure Transfers VM7 Expressway to InvIT Fund

    Published Date : 03 Feb 2026

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    icon-with-text

    4.8 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text